ISPOR - HPR111 Disease Burden and Medical Insurance Expenditure of National Price-Negotiated Drugs for Multiple Sclerosis Under Dual-Channel Model in China: A Budget Impact Model

HPR111 Disease Burden and Medical Insurance Expenditure of National Price-Negotiated Drugs for Multiple Sclerosis Under Dual-Channel Model in China: A Budget Impact Model

Abstract

Authors

Z Zhao M Hu

Full Text Cite This Article

Back to Volume 27, Supplemental Issue 6S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now